



# Adult Respiratory Syncytial Virus (RSV) Session

**Camille Kotton, MD**

**Chair, Adult RSV Work Group**

Advisory Committee on Immunization Practices (ACIP)

June 21, 2023

# Adult RSV Work Group Membership

## ACIP Voting Members

Camille Kotton (Chair)

Keipp Talbot

Sarah Long

## Ex Officio Members

Rachel Zhang (FDA)

Judy Beeler (FDA)

Nicholas Geagan (FDA)

Nadine Peart Akindele (FDA)

Sonnie Kim (NIH/NIAID)

Jeffrey Kelman (CMS)

Valerie Marshal (OIDP)

## CDC Co-Leads

Michael Melgar

Amadea Britton

## Consultants

Robert Atmar (Baylor College of Medicine)

Helen Chu (University of Washington)

Peter Donofrio (Vanderbilt University)

Marie Griffin (Vanderbilt University)

## Liaisons

Kenneth Schmader (AGS)

Vidya Sundareshan (ACP)

Gretchen LaSalle (AAFP)

April Killikelly (NACI, PHAC)

Winnie Su (NACI, PHAC)

Cynthia Lucero-Obusan (Veterans Health Admin.)

Tracy Ruckwardt (NIH/NIAID)

Jonathan Temte (University of Wisconsin)

Katherine Williams (APTR)

Ruth Lynfield (NFID)

Jennifer Heath (AIM)

Steven Pergam (IDSA)

# CDC Contributors

## Coronavirus and Other Respiratory Viruses Division

Lauren Roper

Fiona Havers

Meredith McMorro

Diya Surie

Jennifer DeCuir

Mila Prill

Amanda Payne

Natalie Thornburg

Melissa Coughlin

Jefferson Jones

Katherine Fleming-Dutra

Ismael Ortega Sanchez

## Immunization Safety Office

Anne Hause

David Shay

Christine Olson

## Immunization Services Division

Neil Murthy

Patricia Wodi

Andrew Leidner

Jamison Pike

# Recap of Adult RSV session, February 2023

- Economic analysis of RSV vaccination in older adults (CDC model)
- Comparison of economic analyses of RSV vaccination in older adults (CDC model vs. industry models)
- Evidence to Recommendations framework for use of two RSV vaccines (GSK and Pfizer products) in older adults

# Recent work group discussion

- Review of Season 2 safety and efficacy data from main phase 3 trials of RSV vaccines, as well as coadministration study results (with influenza vaccines)
- Update to GRADE and Evidence to Recommendations for both RSV vaccines, inclusive of Season 2 data
- Update to economic analyses of RSV vaccination in older adults, inclusive of Season 2 data
- Ethics considerations of different RSV vaccine policy recommendations

# Recent work group discussion

- Possible policy recommendations for RSV vaccination of U.S. older adults
  - Should RSV vaccines be recommended for U.S. adults aged  $\geq 65$  years?
  - Should RSV vaccines be recommended for U.S. adults aged 60–64 years?

# Agenda: Wednesday June 21, 2023

- Pfizer safety and efficacy update, including coadministration results  
Dr. Alejandra Gurtman (Pfizer)
- GSK safety and efficacy update, including coadministration results  
Dr. Leonard Friedland (GSK)
- Economic analysis of RSV vaccination among U.S. older adults  
Dr. David Hutton (U. Michigan)
- Comparison of RSV vaccination economic analyses performed by U. Michigan/CDC, Pfizer, and GSK  
Dr. Ismael Ortega Sanchez (CDC)
- Update to Evidence to Recommendations framework for Pfizer and GSK RSV vaccines  
Dr. Michael Melgar (CDC)
- Clinical considerations for use of RSV vaccines in U.S. older adults  
Dr. Amadea Britton (CDC)

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

